The Gonococcus fights back: Is this time a knock out?

Sexually Transmitted Infections

Volumn 86, Issue 6, 2010, Pages 415-421

  Lewis, David A ^a,b,c  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; KANAMYCIN; PENICILLIN G; QUINOLONE DERIVATIVE; SPECTINOMYCIN; SULFONAMIDE; TETRACYCLINE DERIVATIVE;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DNA METABOLISM; DNA SEQUENCE; GENE MUTATION; GONORRHEA; HUMAN; NEISSERIA; NEISSERIA CINEREA; NEISSERIA FLAVESCENS; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS; NEISSERIA PERFLAVA; NEISSERIA POLYSACCHAREA; NONHUMAN; PRIORITY JOURNAL; REVIEW; URETHRITIS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FORECASTING; GONORRHEA; HUMANS; MUTATION; NEISSERIA GONORRHOEAE;

EID: 78449263982     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sti.2010.042648     Document Type: Review

References (113)

1. Hook EW III, Hunter HH. Gonococcal infections in the adult. In: Holmes KK, Sparling PF, Stamm WE, et al, eds. Sexually transmitted diseases. 4th edn. New York: McGraw-Hill Companies, Inc, 2008:627-45.
2. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999;75:3-17.
3. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997;349:1868-73.
4. Tapsall JW, Ndowa F, Lewis DA, et al. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria go1norrhoeae. Expert Rev Anti Infect Ther 2009;7:821-34.
5. Oriel JD. The scars of Venus: a history of venereology. London: Springer-Verlag, 1994.
6. Kampmeier RH. Introduction of sulfonamide therapy for gonorrhea. Sex Transm Dis 1983;10:81-4.
7. Sulphonamide-resistant gonorrhoea. Lancet 1944;ii:693-4.
8. Austin TW, Brooks GF, Bethel M, et al. Gonorrhea. Trimethoprim- sulfamethoxazole in the treatment of gonococcal urethritis: clinical and laboratory correlates. J Infect Dis 1973;128(Suppl):666-72.
9. Lawrence A, Phillips I, Nicol C. Various regimens of trimethoprim- sulfamethoxazole used in the treatment of gonorrhea. J Infect Dis 1973;128:673-8.
10. Johnson SR, Morse SA. Antibiotic resistance in Neisseria gonorrhoeae: genetics and mechanisms of resistance. Sex Transm Dis 1988;15:217-24.
11. Wainwright M, Swan HT. C.G. Paine and the earliest surviving clinical records of penicillin therapy. Med Hist 1986;30:42-56. (Pubitemid 16172927)
12. Penicillin in gonorrhoea. Lancet 1944;i:345-6.
13. Van Slyke CJ, Arnold RC, Buchholtz M. Penicillin therapy in sulfonamide-resistant gonorrhea in men. Am J Public Health Nations Health 1943;33:1392-4.
14. Mahoney JF, Arnold RC, Harris A. Penicillin treatment of early syphilis - a preliminary report. Am J Public Health Nations Health 1943;33:1387-91.
15. Martin JE Jr, Lester A, Price EV, et al. Comparative study of gonococcal susceptibility to penicillin in the United States, 1955-1969. J Infect Dis 1970;122:459-61.
16. Reyn A, Korner B, Bentzon MW. Effects of penicillin, streptomycin, and tetracycline on N. gonorrhoeae isolated in 1944 and in 1957. Br J Vener Dis 1958;34:227-39.
17. Jaffe HW, Biddle JW, Thornsberry C, et al. National gonorrhea therapy monitoring study: in vitro antibiotic susceptibility and its correlation with treatment results. N Engl J Med 1976;294:5-9.
18. Brannigan JA, Tirodimos IA, Zhang QY, et al. Insertion of an extra amino acid is the main cause of the low affinity of penicillin-binding protein 2 in penicillin-resistant strains of Neisseria gonorrhoeae. Mol Microbiol 1990;4:913-19.
19. Powell AJ, Tomberg J, Deacon AM, et al. Crystal structures of penicillin-binding protein 2 from penicillin-susceptible and -resistant strains of Neisseria gonorrhoeae reveal an unexpectedly subtle mechanism for antibiotic resistance. J Biol Chem 2009;284:1202-12.
20. Shafer WM, Veal WL, Lee EH, et al. Genetic organization and regulation of antimicrobial efflux systems possessed by Neisseria gonorrhoeae and Neisseria meningitidis. J Mol Microbiol Biotechnol 2001;3:219-24.
21. Veal WL, Nicholas RA, Shafer WM. Overexpression of the MtrC-MtrD-MtrE efflux pump due to an mtrR mutation is required for chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. J Bacteriol 2002;184:5619-24.
22. Olesky M, Hobbs M, Nicholas RA. Identification and analysis of amino acid mutations in porin IB that mediate intermediate-level resistance to penicillin and tetracycline in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2002;46:2811-20.
23. Olesky M, Zhao S, Rosenberg RL, et al. Porin-mediated antibiotic resistance in Neisseria gonorrhoeae: ion, solute, and antibiotic permeation through PIB proteins with penB mutations. J Bacteriol 2006;188:2300-8.
24. Warner PF, Zubrzycki LJ, Chila M. Polygenes and modifier genes for tetracycline and penicillin resistance in Neisseria gonorrhoeae. J Gen Microbiol 1980;117:103-10.
25. Ropp PA, Hu M, Olesky M, et al. Mutations in ponA, the gene encoding penicillin-binding protein 1, and a novel locus, penC, are required for high-level chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2002;46:769-77.
26. Zhao S, Tobiason DM, Hu M, et al. The penC mutation conferring antibiotic resistance in Neisseria gonorrhoeae arises from a mutation in the PilQ secretin that interferes with multimer stability. Mol Microbiol 2005;57:1238-51.
27. Percival A, Rowlands J, Corkill JE, et al. Penicillinase-producing gonococci in Liverpool. Lancet 1976;2:1379-82.
28. Centers for Disease Control and Prevention. Penicillinase-producing Neisseria gonorrhoeae. Morbid Mortal Weekly Rep 1976;33:408-10.
29. Dillon JA, Yeung KH. Beta-lactamase plasmids and chromosomally mediated antibiotic resistance in pathogenic Neisseria species. Clin Microbiol Rev 1989;(Suppl 2):S125-33.
30. Gouby A, Bourg G, Ramuz M. Previously undescribed 6.6-kilobase R plasmid in penicillinase-producing Neisseria gonorrhoeae. Antimicrob Agents Chemother 1986;29:1095-7. (Pubitemid 16084077)
31. Brett M. A novel gonococcal beta-lactamase plasmid. J Antimicrob Chemother 1989;23:653-4.
32. Pagotto F, Aman AT, Ng LK, et al. Sequence analysis of the family of penicillinase-producing plasmids of Neisseria gonorrhoeae. Plasmid 2000;43:24-34.
33. Hu M, Nandi S, Davies C, et al. High-level chromosomally mediated tetracycline resistance in Neisseria gonorrhoeae results from a point mutation in the rpsJ gene encoding ribosomal protein S10 in combination with the mtrR and penB resistance determinants. Antimicrob Agents Chemother 2005;49:4327-34.
34. Roberts MC, Wagenvoort JH, van Klingeren B, et al. tetM- and beta-lactamase-containing Neisseria gonorrhoeae (tetracycline resistant and penicillinase producing) in The Netherlands. Antimicrob Agents Chemother 1988;32:158.
35. Centers for Disease Control (CDC). Tetracycline-resistant Neisseria gonorrhoeae-Georgia, Pennsylvania, New Hampshire. MMWR Morb Mortal Wkly Rep 1985;34:563-4, 569-70.
36. Morse SA, Johnson SR, Biddle JW, et al. High-level tetracycline resistance in Neisseria gonorrhoeae is result of acquisition of streptococcal tetM determinant. Antimicrob Agents Chemother 1986;30:664-70.
37. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001;65:232-60. (Pubitemid 32538179)
38. Gascoyne DM, Heritage J, Hawkey PM, et al. Molecular evolution of tetracycline-resistance plasmids carrying TetM found in Neisseria gonorrhoeae from different countries. J Antimicrob Chemother 1991;28:173-83.
39. Gascoyne-Binzi DM, Heritage J, Hawkey PM. Nucleotide sequences of the tet(M) genes from the American and Dutch type tetracycline resistance plasmids of Neisseria gonorrhoeae. J Antimicrob Chemother 1993;32:667-76.
40. Gascoyne-Binzi DM, Hawkey PM, Heritage J. The distribution of variants of the Tet M determinant in tetracycline-resistant Nisseria gonorrhoeae. J Antimicrob Chemother 1994;33:1011-16.
41. Chalkley LJ, Janse van Rensburg MN, Matthee PC, et al. Plasmid analysis of Neisseria gonorrhoeae isolates and dissemination of tetM genes in southern Africa 1993-1995. J Antimicrob Chemother 1997;40:817-22.
42. Marquez CM, Dillon JA, Rodriguez V, et al. Detection of a novel Tet M determinant in tetracycline-resistant Neisseria gonorrhoeae from Uruguay, 1996-1999. Sex Transm Dis 2002;29:792-7.
43. Telzak EE, Spitalny KC, Faur YC, et al. Risk factors for infection with plasmid-mediated high-level tetracycline resistant Neisseria gonorrhoeae. Sex Transm Dis 1989;16:132-6.
44. Easmon CS, Forster GE, Walker GD, et al. Spectinomycin as initial treatment for gonorrhoea. Br Med J 1984;289:1032-4.
45. Judson FN, Ehret JM, Handsfield HH. Comparative study of ceftriaxone and spectinomycin for treatment of pharyngeal and anorectal gonorrhea. JAMA 1985;253:1417-19.
46. Ashford WA, Potts DW, Adams HJ, et al. Spectinomycin-resistant penicillinase-producing Neisseria gonorrhoeae. Lancet 1981;2:1035-7.
47. Stolz E, Zwart HG, Michel MF. Activity of eight antimicrobial agents in vitro against N. gonorrhoeae. Br J Vener Dis 1975;51:257-64.
48. Berg SW, Harrison WO. Spectinomycin as primary treatment of gonorrhea in areas of high prevalence of penicillinase-producing Neisseria gonorrhoeae. Sex Transm Dis 1981;8:38-9.
49. Boslego JW, Tramont EC, Takafuji ET, et al. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med 1987;317:272-8.
50. Donegan EA, Wirawan DN, Muliawan P, et al. Fluoroquinolone-resistant Neisseria gonorrhoeae in Bali, Indonesia: 2004. Sex Transm Dis 2006;33:625-9.
51. Ieven M, Van Looveren M, Sudigdoadi S, et al. Antimicrobial susceptibilities of Neisseria gonorrhoeae strains isolated in Java, Indonesia. Sex Transm Dis 2003;30:25-9.
52. Daly CC, Hoffman I, Hobbs M, et al. Development of an antimicrobial susceptibility surveillance system for Neisseria gonorrhoeae in Malawi: comparison of methods. J Clin Microbiol 1997;35:2985-8. (Pubitemid 27452451)
53. Lkhamsuren E, Shultz TR, Limnios EA, et al. The antibiotic susceptibility of Neisseria gonorrhoeae isolated in Ulaanbaatar, Mongolia. Sex Transm Infect 2001;77:218-19.
54. Brown LB, Krysiak R, Kamanga G, et al. Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sex Transm Dis 2010;37:169-72.
55. Vakulenko SB, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 2003;16:430-50.
56. Ison CA, Littleton K, Shannon KP, et al. Spectinomycin resistant gonococci. Br Med J 1983;287:1827-9.
57. Fekete T. Antimicrobial susceptibility testing of Neisseria gonorrhoeae and implications for epidemiology and therapy. Clin Microbiol Rev 1993;6:22-33. (Pubitemid 23055192)
58. Brown ST, Pedersen HB, Holmes KK. Comparison of erythromycin base and estolate in gonococcal urethritis. JAMA 1977;238:1371-3.
59. Young H, Moyes A, McMillan A. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. Int J STD AIDS 1997;8:299-302.
60. World Health Organisation. Guidelines for the management of sexually transmitted infections, 2003. http://www.who.int/reproductive-health/ publications/mngt-stis/index.html (accessed 27 Apr 2009).
61. Handsfield HH, Dalu ZA, Martin DH, et al. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group. Sex Transm Dis 1994;21:107-11.
62. Roberts MC. Update on macrolide-lincosamide-streptogramin, ketolide, and oxazolidinone resistance genes. FEMS Microbiol Lett 2008;282:147-59.
63. Zarantonelli L, Borthagaray G, Lee EH, et al. Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. Antimicrob Agents Chemother 1999;43:2468-72.
64. Zarantonelli L, Borthagaray G, Lee EH, et al. Decreased susceptibility to azithromycin and erythromycin mediated by a novel mtr(R) promoter mutation in Neisseria gonorrhoeae. J Antimicrob Chemother 2001;47:651-4.
65. Luna VA, Cousin S Jr, Whittington WL, et al. Identification of the conjugative mef gene in clinical Acinetobacter junii and Neisseria gonorrhoeae isolates. Antimicrob Agents Chemother 2000;44:2503-6.
66. Roberts MC, Chung WO, Roe D, et al. Erythromycin-resistant Neisseria gonorrhoeae and oral commensal Neisseria spp. carry known rRNA methylase genes. Antimicrob Agents Chemother 1999;43:1367-72. (Pubitemid 29259327)
67. Cousin SL Jr, Whittington WL, Roberts MC. Acquired macrolide resistance genes and the 1 bp deletion in the mtrR promoter in Neisseria gonorrhoeae. J Antimicrob Chemother 2003;51:131-3.
68. Ng LK, Martin I, Liu G, et al. Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2002;46:3020-5.
69. Dillon JA, Ruben M, Li H, et al. Challenges in the control of gonorrhea in South America and the Caribbean: monitoring the development of resistance to antibiotics. Sex Transm Dis 2006;33:87-95.
70. Johnson SR, Sandul AL, Parekh M, et al. Mutations causing in vitro resistance to azithromycin in Neisseria gonorrhoeae. Int J Antimicrob Agents 2003;21:414-19.
71. Galarza PG, Abad R, Canigia LF, et al. New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2010;54:1652-3.
72. Galarza PG, Alcala B, Salcedo C, et al. Emergence of high level azithromycin-resistant Neisseria gonorrhoeae strain isolated in Argentina. Sex Transm Dis 2009;36:787-8.
73. Chisholm SA, Neal TJ, Alawattegama AN, et al. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother 2009;64:353-8.
74. Gransden WR, Warren CA, Phillips I, et al. Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin. Lancet 1990;335:51.
75. Tanaka M, Nakayama H, Haraoka M, et al. Antimicrobial resistance of Neisseria gonorrhoeae and high prevalence of ciprofloxacin-resistant isolates in Japan, 1993 to 1998. J Clin Microbiol 2000;38:521-5.
76. Ray K, Bala M, Kumari S, et al. Antimicrobial resistance of Neisseria gonorrhoeae in selected World Health Organization Southeast Asia Region countries: an overview. Sex Transm Dis 2005;32:178-84. (Pubitemid 40271271)
77. Ison CA, Woodford PJ, Madders H, et al. Drift in susceptibility of Neisseria gonorrhoeae to ciprofloxacin and emergence of therapeutic failure. Antimicrob Agents Chemother 1998;42:2919-22.
78. Dan M. The use of fluoroquinolones in gonorrhoea: the increasing problem of resistance. Expert Opin Pharmacother 2004;5:829-54.
79. Lewis DA, Marumo E. Revision of the national guideline for first-line comprehensive management and control of sexually transmitted infections: what's new and why? S Afr J Epid Infect 2009;24:6-9.
80. Martin IM, Ison CA, Aanensen DM, et al. Changing epidemiologic profile of quinolone-resistant Neisseria gonorrhoeae in London. J Infect Dis 2005;192:1191-5.
81. Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men - United States, 2003, and revised recommendations for gonorrhea treatment, 2004. MMWR Morb Mortal Wkly Rep 2004;53:335-8.
82. Belland RJ, Morrison SG, Ison C, et al. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol 1994;14:371-80. (Pubitemid 24325813)
83. Tanaka M, Sakuma S, Takahashi K, et al. Analysis of quinolone resistance mechanisms in Neisseria gonorrhoeae isolates in vitro. Sex Transm Infect 1998;74:59-62.
84. Shultz TR, Tapsall JW, White PA. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC. Antimicrob Agents Chemother 2001;45:734-8.
85. Barry PM, Klausner JD. The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin Pharmacother 2009;10:555-77.
86. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007;44(Suppl 3):S84-101.
87. Ison CA, Mouton JW, Jones K, et al. Which cephalosporin for gonorrhoea? Sex Transm Infect 2004;80:386-8.
88. Lo JY, Ho KM, Leung AO, et al. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother 2008;52:3564-7.
89. Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 2008;148:606-13.
90. Ito M, Yasuda M, Yokoi S, et al. Remarkable increase in central Japan in 2001-2002 of Neisseria gonorrhoeae isolates with decreased susceptibility to penicillin, tetracycline, oral cephalosporins, and fluoroquinolones. Antimicrob Agents Chemother 2004;48:3185-7.
91. Deguchi T, Yasuda M, Yokoi S, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother 2003;9:35-9. (Pubitemid 36504368)
92. Muratani T, Inatomi H, Ando Y, et al. Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol 2008;15:837-42.
93. Tapsall JW. Implications of current recommendations for third-generation cephalosporins use in the WHO Western Pacific region following the emergence of multi-resistant gonococci. Sex Transm Infect 2009;85:256-8.
94. Martin IM, Hoffmann S, Ison CA. European Surveillance of Sexually Transmitted Infections (ESSTI): the first combined antimicrobial susceptibility data for Neisseria gonorrhoeae in Western Europe. J Antimicrob Chemother 2006;58:587-93.
95. WHO Western Pacific Gonococcal Antimicrobial Surveillance Programme. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2006. Commun Dis Intell 2008;32:48-51.
96. Wang SA, Lee MV, O'Connor N, et al. Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime-Hawaii, 2001. Clin Infect Dis 2003;37:849-52.
97. Tapsall JW, Ray S, Limnios A. Characteristics and population dynamics of mosaic penA allele-containing Neisseria gonorrhoeae isolates collected in Sydney, Australia, in 2007-2008. Antimicrob Agents Chemother 2010;54:554-6.
98. Tapsall J, Read P, Carmody C, et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009;58:683-7.
99. Ito M, Deguchi T, Mizutani KS, et al. Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan. Antimicrob Agents Chemother 2005;49:137-43.
100. Ameyama S, Onodera S, Takahata M, et al. Mosaic-like structure of penicillin-binding protein 2 gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents Chemother 2002;46:3744-9. (Pubitemid 35403246)
101. Tanaka M, Nakayama H, Huruya K, et al. Analysis of mutations within multiple genes associated with resistance in a clinical isolate of Neisseria gonorrhoeae with reduced ceftriaxone susceptibility that shows a multidrug-resistant phenotype. Int J Antimicrob Agents 2006;27:20-6.
102. Osaka K, Takakura T, Narukawa K, et al. Analysis of amino acid sequences of penicillin-binding protein 2 in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime and ceftriaxone. J Infect Chemother 2008;14:195-203.
103. Takahata S, Senju N, Osaki Y, et al. Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 2006;50:3638-45.
104. Zhao S, Duncan M, Tomberg J, et al. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2009;53:3744-51.
105. Ochiai S, Ishiko H, Yasuda M, et al. Rapid detection of the mosaic structure of the Neisseria gonorrhoeae penA Gene, which is associated with decreased susceptibilities to oral cephalosporins. J Clin Microbiol 2008;46:1804-10.
106. Whiley DM, Limnios EA, Ray S, et al. Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone. Antimicrob Agents Chemother 2007;51:3111-16. (Pubitemid 350067516)
107. Lindberg R, Fredlund H, Nicholas R, et al. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother 2007;51:2117-22.
108. Lee SG, Lee H, Jeong SH, et al. Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone. J Antimicrob Chemother 2010;65:669-75.
109. Ochiai S, Sekiguchi S, Hayashi A, et al. Decreased affinity of mosaic-structure recombinant penicillin-binding protein 2 for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob Chemother 2007;60:54-60.
110. Livermore DM, Alexander S, Marsden B, et al. Activity of ertapenem against Neisseria gonorrhoeae. J Antimicrob Chemother 2004;54:280-1.
111. Deshpande LM, Gales AC, Jones RN. GAR-936 (9-t-butylglycylamido- minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria. Int J Antimicrob Agents 2001;18:29-35.
112. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-86.
113. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007;20:440-58, table of contents.